Literature DB >> 18288122

A gestation- and postnatal age-based reference chart for assessing renal function in extremely premature infants.

S Thayyil1, S Sheik, S T Kempley, A Sinha.   

Abstract

OBJECTIVE: A single value of plasma creatinine cannot be used to define renal dysfunction in premature babies, as levels are influenced by gestation and postnatal age. The aim of this study was to create reference ranges for plasma creatinine in cohort of extremely premature infants. STUDY
DESIGN: Retrospective analysis of plasma creatinine levels in the first 8 weeks of life from 161 consecutively admitted premature infants 28 weeks gestation. RESULT: Babies were divided into three groups according to gestation. Peak (10th, 90th percentiles) creatinine levels were 132 (106,162) in 22 to 24 weeks gestational infants, 127 (89,151) in those from 25 to 26 weeks and 110 (87,134) in those from 27 to 28 weeks (P<0.001). Creatinine at birth was similar across the groups with levels increasing during the first few days. It decreases thereafter before reaching stable levels by 5 weeks of age.
CONCLUSION: Gestation- and age-based reference charts should be used for interpretation of creatinine values in extremely premature babies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288122     DOI: 10.1038/sj.jp.7211905

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  20 in total

1.  Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates.

Authors:  Isabel George; Djalila Mekahli; Maissa Rayyan; Elena Levtchenko; Karel Allegaert
Journal:  Pediatr Nephrol       Date:  2011-04-17       Impact factor: 3.714

Review 2.  Clinical trials of medicines in neonates: the influence of ethical and practical issues on design and conduct.

Authors:  Mark A Turner
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

3.  Comparison of Amikacin Pharmacokinetics in Neonates Following Implementation of a New Dosage Protocol.

Authors:  Kaitlin M Hughes; Peter N Johnson; Michael P Anderson; Kris C Sekar; Robert C Welliver; Jamie L Miller
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jan-Feb

4.  Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin.

Authors:  J E Constance; D Reith; R M Ward; A Balch; C Stockmann; E K Korgenski; E A Thorell; C M T Sherwin
Journal:  J Perinatol       Date:  2017-06-08       Impact factor: 2.521

5.  Relationship of maternal creatinine to first neonatal creatinine in infants <30 weeks gestation.

Authors:  A S Weintraub; A Carey; J Connors; V Blanco; R S Green
Journal:  J Perinatol       Date:  2015-01-15       Impact factor: 2.521

6.  Characterization of the vitamin A transport in preterm infants after repeated high-dose vitamin A injections.

Authors:  A C Longardt; B Schmiedchen; J Raila; F J Schweigert; M Obladen; C Bührer; A Loui
Journal:  Eur J Clin Nutr       Date:  2014-10-15       Impact factor: 4.016

7.  Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants.

Authors:  Zhiping Li; Yewei Chen; Qin Li; Di Cao; Wenjing Shi; Yun Cao; Dan Wu; Yiqing Zhu; Yi Wang; Chao Chen
Journal:  Eur J Clin Pharmacol       Date:  2013-01-26       Impact factor: 2.953

8.  The spectrum of onset of acute kidney injury in premature infants less than 30 weeks gestation.

Authors:  A S Weintraub; J Connors; A Carey; V Blanco; R S Green
Journal:  J Perinatol       Date:  2016-01-21       Impact factor: 2.521

9.  Longitudinal analysis of serum cystatin C for estimating the glomerular filtration rate in preterm infants.

Authors:  Toshinori Nakashima; Hirosuke Inoue; Junko Fujiyoshi; Naoko Matsumoto
Journal:  Pediatr Nephrol       Date:  2016-01-25       Impact factor: 3.714

Review 10.  Assessment of kidney function in preterm infants: lifelong implications.

Authors:  Carolyn L Abitbol; Marissa J DeFreitas; José Strauss
Journal:  Pediatr Nephrol       Date:  2016-02-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.